Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.74 |
| ▸ | CTSK | P43235 | 5/20 | 0.74 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | CHRND | Q07001 | 5/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.56 |
| ▸ | CHRNG | P07510 | 1/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | PTPRA | P18433 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927886 | 0.99 | CTSS (0.73) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL2922548 | 0.99 | CTSS (0.73) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL2928795 | 0.95 | CTSS (0.78) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL5665787 | 0.94 | CTSS (0.67) | CTSSCTSKGRIA1CHRNDCHRNA1 | |
| SCHEMBL21318569 | 0.94 | CTSS (0.67) | CTSSCTSKGRIA1CHRNDCHRNA1 | |
| SCHEMBL11681623 | 0.93 | CTSS (0.69) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL16909091 | 0.92 | CTSS (0.68) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL16909092 | 0.92 | CTSS (0.68) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL20866077 | 0.91 | CTSS (0.73) | CTSSCTSKCTSLCTSBGRIA1 | |
| SCHEMBL21068130 | 0.91 | CTSS (0.73) | CTSSCTSKCTSLCTSBGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470101-B1 | NEW OPIOID DERIVATIVE | TEIKOKU SEIYAKU KK (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-6838580-B2 | Opioid derivative | TEIKOKU SEIYAKU CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20030171302-A1 | Opioid derivative | TEIKOKU SEIYAKU CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171302-A1 | Opioid derivative | OPRD1, OPRM1, OPRK1 | CTSS 4429/4885CTSK 4478/4885CTSL 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.